News summarySEC EDGARNov 5, 2026, 12:00 PM
Xeris Biopharma, 8-K (2.02, 9.01): reported results of operations
Xeris Biopharma reported third-quarter 2026 revenue of $107.2 million, up 44% year over year, and net income of $11.3 million; it raised 2026 revenue guidance to $395 million–$405 million and its 2030 outlook to more than $1 billion.